Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{185675,
        author = {Dornala Chaitanya Dixit and Shaik. Mahammad Rafi},
        title = {3D Printing of Pharmaceuticals: A New Era of Personalized Medicine and On-Demand Drug Manufacturing},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {12},
        number = {5},
        pages = {3282-3286},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=185675},
        abstract = {Three-dimensional printing (3DP) or additive manufacturing has been one of the most disruptive technologies of the 21st century. Ever since stereo lithography was introduced by Chuck Hull in 1986, several methods such as selective laser sintering, fused deposition modeling, and binder jetting have been created, and each of them widened the application of 3DP. Initially used for prototyping and industrial design, 3DP now has urgent uses in healthcare and the pharmaceutical sciences. The technology allows for the construction of intricate structures with high accuracy, patient-specific dosage forms, on-demand production, and drug delivery systems with tailored release profiles. 3DP innovations include Polypills, tablets that are chewable or Braille-imprinted, and implants with active pharmaceutical ingredients. These abilities create new opportunities in drug discovery, preclinical screening, and clinical practice by reducing the cost of development, decreasing the rate of drug failure, and increasing patient compliance. In the pharmaceutical industry, 3DP has a huge economic and logistical advantage by decentralizing manufacturing, minimizing storage and transport requirements, and allowing immediate response to patient demand. But despite this, there are challenges such as limited pharmaceutical-grade printable materials, quality control problems, regulatory doubts, and production scalability. These hurdles notwithstanding, ongoing advances in material science, printer technology, and digital manufacturing, coupled with changing regulatory environments, should drive clinical take-up. In general, 3DP is a paradigm shift from conventional mass production to tailored medicine. By closing the loop between digital design and physical fabrication, it has the potential to transform pharmaceutical development and delivery in the very near future.},
        keywords = {3D Printing(3DP) / Additive Manufacturing, Patient-specific dosage, Tailored drug release, Polypills, Chewable / Braille tablets, Implants with APIs, On-demand production, Decentralized manufacturing, Cost reduction, Regulatory challenges, Quality control.},
        month = {October},
        }